Overview

OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277

Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The study is an open-label extension study, offering patients who participated and completed previous studies 901 and 910 (an extension to 901) to continue treatment with DiaPep277 and clinical follow-up, for up to 3 additional years.The aim of the study is to collect safety and efficacy data of long term treatment effect of Diapep277.Only patients who completed studies 901 or 910 and still have stimulated C-peptide level equal to or above 0.2 nmol/L will be eligible for this extension study
Phase:
Phase 3
Details
Lead Sponsor:
Rabin Medical Center